TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18077189
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) of 40 mg triamcinolone acetonide and 1% lidocaine
Study: 11212161
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg alendronate (ALN)
Study: 11212161
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate (ALN)
Study: 11212161
Drug: Any dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any dose of alendronate (ALN)
Study: 11212161
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg and 10 mg alendronate (ALN)
Study: 25428566
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy with wrist orthosis
Study: 19013107
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m²) plus gemcitabine (1000 mg/m²) followed by docetaxel (60 mg/m²)
Study: 19013107
Drug: Paclitaxel (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (225 mg/m²) plus carboplatin (AUC=6)
Study: 3330028
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine 20 mg b.d.
Study: 3330028
Drug: Cyclopenthiazide 0.25
Normalized name: cyclopenthiazide 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopenthiazide 0.25 mg with 8.1 mmol potassium daily
Study: 11579708
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/day orally)
Study: 778306
Drug: Ribavirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (600 mg/day in three divided doses)
Study: 28877715
Drug: Oral Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Pirfenidone
Study: 23440694
Drug: IL-10 level
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 level >8 pg/ml (pre-IVIG)
Study: 23440694
Drug: TNFα level
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNFα level <2 pg/ml (pre-IVIG)
Study: 12687332
Drug: gemfibrozil and
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil and itraconazole combination
Study: 2187175
Drug: Nebulized metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized metaproterenol sulfate 5% inhalant solution at a dose of 0.02 mL/kg
Study: 26156737
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg vitamin D₃/d
Study: 26156737
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vitamin D₃/d
Study: 23816038
Drug: Nurse telephone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse telephone intervention providing monthly self-management support and quarterly medication management facilitation
Study: 10779419
Drug: BFM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFM treatment without cranial irradiation
Study: 15963199
Drug: Salmeterol 25
Normalized name: fluticasone-salmeterol 250 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) via HFA-MDI
Study: 15963199
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg/fluticasone propionate 250 microg (one puff, twice daily) via Diskus inhaler
Study: 12110626
Drug: Multidrug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug treatment (MDT)
Study: 7437209
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic requirement (women)
Study: 7437209
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic requirement (men)
Study: 24597840
Drug: Luseogliflozin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 0.5 mg
Study: 25855342
Drug: Luseogliflozin 1
Normalized name: luseogliflozin
DrugBank: Luseogliflozin (DB12214)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Luseogliflozin 1 mg
Study: 24597840
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg
Study: 24597840
Drug: Luseogliflozin 5
Normalized name: luseogliflozin
DrugBank: Luseogliflozin (DB12214)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Luseogliflozin 5 mg
Study: 19665366
Drug: Heated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated intravenous fluids (via Hotline fluid warmer)
Study: 11682423
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 1 mg/kg combined with 50 microg/kg of morphine
Study: 11682423
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 50 microg/kg
Study: 9021940
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in group 1 (normal renal function)
Study: 7889965
Drug: Single-dose cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cefuroxime (20 mg/kg intravenously at induction of anaesthesia)
Study: 7889965
Drug: Three-day course
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day course of cefuroxime (20 mg/kg intravenously at induction followed by 750 mg t.i.d. for three consecutive days)
Study: 2851413
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 7500 AXaU, subcutaneously, starting 2 hours before surgery and continuing for 7 days
Study: 29504044
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen (60,000 IU weekly)
Study: 18760150
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills treatment program (12-week program with weekly 3-hour group sessions and 1-hour individual sessions)
Study: 11205721
Drug: Specific and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific and individualized treatment for diastolic heart failure (DHF)
Study: 8737632
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sustained release film tablets
Study: 8737632
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution (1 x 1000 mg/d)
Study: 1410128
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg velnacrine maleate
Study: 28579313
Drug: Probiotic soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic soy milk (200 mL/day)
Study: 28328980
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of cerebral oxygenation by near-infrared spectroscopy with treatment guidelines
Study: 22638708
Drug: Intensive nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive nutritional intervention comprising regular dietetic counseling and oral nutritional supplementation for 3 months postoperatively
Study: 18270213
Drug: CCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCM treatment for 3 months
Study: 18270213
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 3 months
Study: 22125782
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of prednisolone daily for 14 days
Study: 14662044
Drug: Paclitaxel 230
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 230 mg/m2 plus topotecan (Arm 3, 13 patients)
Study: 7675940
Drug: NNC 756
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC 756 (80 mg)
Study: 2088189
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg) intravenously every 12 h
Study: 2088189
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g) intravenously every 8 h
Study: 230654
Drug: Arginine vasotocin
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasotocin (AVT) administered subcutaneously at 22.00 and 01.00 h, doses between 2 and 12 micrograms
Study: 22902795
Drug: Argentine tango
Normalized name: Argentine canola pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argentine tango dance program (12 months, twice-weekly classes)
Study: 18414100
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost applied once daily for 7 days in one-eye trials
Study: 18414100
Drug: Bilateral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral treatment with latanoprost
Study: 18414100
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of fellow eyes in bilateral treatment
Study: 18414100
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of baseline IOP at each time point between fellow eyes in one-eye trials and bilateral treatment
Study: 16625522
Drug: etifoxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: etifoxine (50 mg tid)
Study: 6293834
Drug: Bacmecillinam 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacmecillinam 100 mg
Study: 6293834
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Bacmecillinam 400 mg vs Pivmecillinam 400 mg
Study: 30859975
Drug: Aripiprazole Once-Monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole Once-Monthly 400mg (AOM 400) administered every 4 weeks for up to 52 weeks
Study: 30859975
Drug: Aripiprazole Once-Monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole Once-Monthly 400mg (AOM 400)
Study: 24281275
Drug: Ropivacaine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine continuous infusion
Study: 18334909
Drug: Iloperidone 24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 24 mg/d
Study: 19375893
Drug: Ziprasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 160 mg/d
Study: 15704615
Drug: Esomeprazole MUPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole MUPS 40 mg tablets without hard gelatine capsule (Reference)
Study: 16189197
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH
Study: 10417491
Drug: Nebuliser solution
Normalized name: Pentamidine isetionate 300 mg powder for nebuliser solution vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuliser solution plus isotonic saline (20 mg)
Study: 10417491
Drug: Nebuliser solution
Normalized name: Pentamidine isetionate 300 mg powder for nebuliser solution vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuliser solution plus saline and procaterol (20 mg)
Study: 8853774
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (4 g daily for 12 months)
Study: 8853774
Drug: Liquid paraffin
Normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid paraffin capsules (placebo)
Study: 1346877
Drug: TRH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH treatment (4 doses of 400 micrograms 8‐hourly)
Study: 11230588
Drug: TRH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH treatment
Study: 6140699
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg + Placebo (Ethanol 0.1 g/kg)
Study: 6140699
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg + Placebo (Ethanol 0.1 g/kg)
Study: 2895705
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg
Study: 27600257
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% topical gel
Study: 12021827
Drug: Citicoline 500
Normalized name: citicoline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 500 mg orally once daily for 6 weeks
Study: 9892879
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for 4 or 8 weeks
Study: 11220352
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg of starch)
Study: 29278278
Drug: Linaclotide 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 0.125 mg
Study: 29278278
Drug: Linaclotide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 0.25 mg
Study: 29278278
Drug: Linaclotide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 0.5 mg
Study: 9026280
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GnRH agonist
Study: 2055292
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Study: 2055292
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Study: 3707649
Drug: Ibopamine 50
Normalized name: ibopamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 50 mg
Study: 1678273
Drug: Ibopamine 100
Normalized name: ibopamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 100 mg
Study: 30817764
Drug: Patterned, frequency-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patterned, frequency-modulated oral stimulation via the NTrainer system through a pulsatile pacifier
Study: 24697925
Drug: Control (intravenous/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intravenous/oral placebo)
Study: 773414
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% ointment
Study: 11153592
Drug: auto-CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: auto-CPAP treatment
Study: 11153592
Drug: conventional CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional CPAP treatment
Study: 28755782
Drug: Romosozumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (210 mg once monthly)
Study: 27487526
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 µg once daily)
Study: 28153659
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg (4000 IU) by subcutaneous injection daily from recruitment until 36+0 weeks or delivery
Study: 22784845
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU vitamin D3 daily for 6 months
Study: 22784845
Drug: 2,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 IU vitamin D3 daily for 6 months
Study: 18979150
Drug: Tocilizumab placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab placebo plus MTX 8 mg/week
Study: 18979150
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg every 4 weeks plus MTX placebo
Study: 2691694
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antihypertensive treatment)
Study: 1190102
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 2 g of vitamin C
Study: 26213879
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration alone
Study: 23580740
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of methylphenidate (MPH)
Study: 17868717
Drug: Brachytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy with a highest dose covering at least 90% of the prostate of 100% or greater
Study: 11347755
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg ramipril
Study: 3540222
Drug: Instant-release verapamil
Normalized name: verapamil Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant-release verapamil (80 mg tablets, 160 mg twice daily)
Study: 27417317
Drug: Cabazitaxel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (20 mg/m² every 3 weeks)
Study: 27417317
Drug: Cabazitaxel (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (8.4 mg/m² weekly)
Study: 7778548
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 10 mg twice daily)
Study: 2389694
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg every 6 hours for 6 days)
Study: 2389694
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg daily for 7 days)
Study: 30270543
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) monotherapy
Study: 18654870
Drug: Undiluted smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted smallpox vaccine
Study: 11328240
Drug: Morning bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning bright light therapy (2500 lux)
Study: 11328240
Drug: Afternoon bright
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afternoon bright light therapy (2500 lux)
Study: 7924594
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy plus chemotherapy
Study: 7924594
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy and chemotherapy
Study: 7924594
Drug: 5-FU given
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU given as continuous infusion
Study: 11200144
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment
Study: 3123540
Drug: Cromolyn 20
Normalized name: cromolyn 20 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn 20 mg
Study: 6402959
Drug: Cromolyn 40
Normalized name: cromolyn 40 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn 40 mg
Study: 3131405
Drug: Cromolyn 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn 60 mg
Study: 25355775
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal therapy (RCT)
Study: 7880658
Drug: Colloid (hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid (hydroxyethyl starch) 7.5 ml kg‐1
Study: 7880658
Drug: Crystalloid (lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid (lactated Ringer's) 15 ml kg‐1
Study: 3284218
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.3 mg/kg body weight)
Study: 29105107
Drug: SPF 70
Normalized name: Coppertone Kids Sunscreen SPF 70
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 70 lotion sunscreen applied at a dosage of 2 mg cm‐2 on half of the face
Study: 29105107
Drug: SPF 70
Normalized name: Coppertone Kids Sunscreen SPF 70
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 70 spray sunscreen applied at a dosage of 2 mg cm‐2 on one of the forearms
Study: 20599042
Drug: Idebenone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (5, 15, and 45 mg/kg, administered orally 3 times a day for 6 months)
Study: 17142216
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin
Study: 12685385
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg twice a day for 7 days
Study: 29507952
Drug: 5-component health
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-component health care professional HPV vaccine communication intervention
Study: 22364690
Drug: Torsemide (1/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide (1/10 of the daily furosemide dose divided into twice daily dosing)
Study: 20966667
Drug: Single-shot femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot femoral nerve block (SSFNB) with concurrent PCA opioids
Study: 1588374
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HIDAC) 3 g/m2 ara-C infused over 3 hours at 12-hour intervals on days 1, 3, and 5
Study: 1588374
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HIDAC)
Study: 31476786
Drug: Antenatal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal administration of betamethasone
Study: 31510777
Drug: No carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No carvedilol therapy (control)
Study: 19746764
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid (AzA) gel 15% applied twice daily
Study: 15491065
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 or 20 mg/day)
Study: 10762562
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Clarithromycin + Rifabutin)
Study: 8732472
Drug: Premarin 0.625
Normalized name: Premarin 0.625mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 0.625 mg/day